Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Share Purchase Price: 1411.09 pence per share.
- Transaction Date: October 3, 2014.
- Shares Acquired: 61,832 Ordinary Shares.
Material Changes
The filing details an increase in the interest of a connected person, Mrs. K Thomson, following the re-investment of a dividend paid to shareholders on October 2, 2014. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a connected person's shareholding change in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the total dividend reinvestment program details for the October 2, 2014 payment date.
- Confirm the current share price relative to the 1411.09 pence transaction price.
- Note that this filing does not contain quarterly or annual financial performance data.